Cutaneous T-Cell Lymphoma

The combination of mogamulizumab and topical steroids conferred favorable outcomes to patients with previously treated cutaneous T-cell lymphoma, according to study results presented at Society of Hematologic Oncology Annual Meeting.

A phase 3 trial designed to evaluate SGX301 for treatment of cutaneous T-cell lymphoma met its primary endpoint, according to the agent’s manufacturer.